[go: up one dir, main page]

MX2018003697A - Metodos para el tratamiento de linfoma difuso de linfocitos b grandes y uso de biomarcadores como predictores de receptividad a farmacos. - Google Patents

Metodos para el tratamiento de linfoma difuso de linfocitos b grandes y uso de biomarcadores como predictores de receptividad a farmacos.

Info

Publication number
MX2018003697A
MX2018003697A MX2018003697A MX2018003697A MX2018003697A MX 2018003697 A MX2018003697 A MX 2018003697A MX 2018003697 A MX2018003697 A MX 2018003697A MX 2018003697 A MX2018003697 A MX 2018003697A MX 2018003697 A MX2018003697 A MX 2018003697A
Authority
MX
Mexico
Prior art keywords
responsiveness
drugs
methods
biomarkers
predictor
Prior art date
Application number
MX2018003697A
Other languages
English (en)
Inventor
Gandhi Anita
Hagner Patrick
POURDEHNAD Michael
William Burnell Trotter Matthew
Risueno-Perez Alberto
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MX2018003697A publication Critical patent/MX2018003697A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

En un aspecto, se proporcionan en la presente métodos para predecir la receptividad de los pacientes con DLBCL al tratamiento con lenolidomida o el Compuesto A; o un estereoisómero de estos; o una sal, solvato, hidrato, cocristal, clatrato farmacéuticamente aceptable de estos; o un polimorfo de estos mediante el uso de biomarcadores o clasificadores que se correlacionan con la receptividad a uno de estos fármacos. En otro aspecto, se proporcionan en la presente métodos para tratar a un paciente con DLBCL que se determinó que es receptivo al tratamiento con lenolidomida o Compuesto A; o un estereoisómero de estos; o una sal, solvato, hidrato, cocristal o clatrato farmacéuticamente aceptable de estos; o un polimorfo de estos mediante el uso de biomarcadores o clasificadores (o productos de estos) que se correlacionan con la receptividad a uno de estos fármacos.
MX2018003697A 2015-09-25 2016-09-22 Metodos para el tratamiento de linfoma difuso de linfocitos b grandes y uso de biomarcadores como predictores de receptividad a farmacos. MX2018003697A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562233181P 2015-09-25 2015-09-25
US201662324829P 2016-04-19 2016-04-19
PCT/US2016/053092 WO2017053555A1 (en) 2015-09-25 2016-09-22 Methods for treating diffuse large b-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs

Publications (1)

Publication Number Publication Date
MX2018003697A true MX2018003697A (es) 2018-08-01

Family

ID=58387244

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003697A MX2018003697A (es) 2015-09-25 2016-09-22 Metodos para el tratamiento de linfoma difuso de linfocitos b grandes y uso de biomarcadores como predictores de receptividad a farmacos.

Country Status (9)

Country Link
US (2) US10689708B2 (es)
EP (1) EP3352756A1 (es)
JP (1) JP2018529344A (es)
KR (1) KR20180052747A (es)
AU (1) AU2016326499A1 (es)
CA (1) CA2999179A1 (es)
IL (1) IL258094A (es)
MX (1) MX2018003697A (es)
WO (1) WO2017053555A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3077548B1 (en) 2013-12-06 2021-11-10 Celgene Corporation Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers
WO2016196580A1 (en) 2015-06-02 2016-12-08 Celgene Corporation Methods for determining drug efficacy for treatment of cancer using ratios of cereblon associated proteins
KR20180095094A (ko) 2016-01-08 2018-08-24 셀진 코포레이션 암을 치료하기 위한 방법 및 치료요법에 대한 임상 감수성의 예측변수로서 바이오마커의 용도
WO2018144445A1 (en) * 2017-01-31 2018-08-09 Celgene Corporation Methods for treating hematological cancer and the use of biomarkers as a predictor for responsiveness to treatment compounds
EP4617665A1 (en) 2024-03-14 2025-09-17 Centre National de la Recherche Scientifique An in vitro method for establishing the prognosis of a subject diagnosed as suffering or having suffered from a diffuse large b-cell lymphoma
WO2025191110A1 (en) 2024-03-14 2025-09-18 Centre National De La Recherche Scientifique An in vitro method for establishing the prognosis of a subject diagnosed as suffering or having suffered from a diffuse large b-cell lymphoma

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6773897B2 (en) * 2000-09-29 2004-08-10 The Johns Hopkins University School Of Medicine Method of predicting the clinical response to chemotherapeutic treatment with alkylating agents
EP2157524A3 (en) * 2003-09-03 2010-12-08 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods for identifying, diagnosing, and predicting survival of lymphomas
US7893045B2 (en) * 2007-08-07 2011-02-22 Celgene Corporation Methods for treating lymphomas in certain patient populations and screening patients for said therapy
US9617600B2 (en) * 2009-04-18 2017-04-11 Genentech, Inc. Methods for assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibodies
US9605320B2 (en) * 2011-01-13 2017-03-28 The Board Of Trustees Of The Leland Stanford Junior University Method of predicting responsiveness of B cell lineage malignancies to active immunotherapy
CA2834535A1 (en) 2011-04-29 2012-11-01 Celgene Corporation Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
EP3904875B1 (en) 2012-06-29 2024-11-20 Celgene Corporation Methods for determining drug efficacy using ikzf3 (aiolos)
EA029485B1 (ru) * 2012-08-09 2018-04-30 Селджин Корпорейшн Способы лечения рака, выбранного из лимфомы, лейкоза, миеломы, глиобластомы, рака ободочной и прямой кишки и печеночно-клеточной карциномы, с использованием 3-(4-((4-(морфолинометил)бензил)окси)-1-оксоизоиндолин-2-ил)пиперидин-2,6-диона
TW201534305A (zh) * 2013-05-03 2015-09-16 Celgene Corp 使用組合療法治療癌症之方法
US20160312292A1 (en) 2013-12-06 2016-10-27 Celgene Corporation Methods for treating hematological cancers and the use of biomarkers as a predictor of clinical sensitivity to immunodulatory therapies
EP3077548B1 (en) * 2013-12-06 2021-11-10 Celgene Corporation Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers
US20170242014A1 (en) 2014-10-13 2017-08-24 Celgene Corporaton Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
WO2016196580A1 (en) 2015-06-02 2016-12-08 Celgene Corporation Methods for determining drug efficacy for treatment of cancer using ratios of cereblon associated proteins
WO2017024019A1 (en) 2015-08-04 2017-02-09 Celgene Corporation Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
US20180231561A1 (en) 2015-08-12 2018-08-16 Celgene Corporation Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
KR20180095094A (ko) 2016-01-08 2018-08-24 셀진 코포레이션 암을 치료하기 위한 방법 및 치료요법에 대한 임상 감수성의 예측변수로서 바이오마커의 용도

Also Published As

Publication number Publication date
KR20180052747A (ko) 2018-05-18
EP3352756A1 (en) 2018-08-01
WO2017053555A1 (en) 2017-03-30
WO2017053555A8 (en) 2017-06-08
US20210102257A1 (en) 2021-04-08
AU2016326499A1 (en) 2018-04-12
US10689708B2 (en) 2020-06-23
JP2018529344A (ja) 2018-10-11
IL258094A (en) 2018-06-28
CA2999179A1 (en) 2017-03-30
US20170088901A1 (en) 2017-03-30

Similar Documents

Publication Publication Date Title
ZA201907607B (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
MX2018003697A (es) Metodos para el tratamiento de linfoma difuso de linfocitos b grandes y uso de biomarcadores como predictores de receptividad a farmacos.
MX2016015181A (es) Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
MY186977A (en) Tetrasubstituted alkene compounds and their use
EP3077548A4 (en) Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
MX370611B (es) Metodos utiles en la sintesis de analogos de halicondrina b.
HK1220980A1 (zh) 用於治疗庞贝氏症的方法和组合物
MX2017007707A (es) Metodo para predecir respuesta a agentes terapeuticos de cancer de mama y metodo de tratamiento de cancer de mama.
PH12016500270A1 (en) Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases
PL3204400T3 (pl) 17α,21-diestry korteksolonu do zastosowania w leczeniu guzów nowotworowych
CL2017000050A1 (es) Terapia de combinación para el cáncer
EP2996721A4 (en) Methods and compositions for prognosis, diagnosis and treatment of adam8-expressing cancer
WO2014197835A3 (en) Methods and compositions for the treatment of cancer
EP2994134A4 (en) Methods of administering dantrolene for the acute treatment of cardiac arrhythmias
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
WO2014146111A3 (en) Analgesic compounds and methods of use
HUE052395T2 (hu) Benzimidazol-származékok mint NAV 1.7 (nátriumcsatorna, feszültségkapuzott, IX típusú, alfa alegység (SCN9A) inhibitorok fájdalom, diszúria és szklerózis multiplex kezelésére
EA201690376A1 (ru) Ингибиторы дезоксицитидинкиназы
MX394633B (es) Profarmacos de antagonista de (s)-1-fenil-2-(piridin-2-il)etanamina (nmda)
MX2016011706A (es) Formulaciones de progesterona.
EP3145507A4 (en) Aza-ellipticine analogs, methods of synthesis and methods of treatment
MX370540B (es) Combinaciones de amida de ácido 4-[(s) -2-azetidin-1-il-1-(4-cloro -3-trifluorometil - fenil) - etilamino] -quinazolin-8-carboxílico e inhibidores de her2 para usarse en el tratamiento de cáncer.
CA2864092A1 (en) Detection and treatment of cd30+ cancers
UA100326U (ru) Применение натриевой соли гидрогенсульфида для потенцирования анальгетического эффекта нестероидных противовоспалительных препаратов